JP2024537619A - 中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての2-アミノ-5,5-ジメチルヘキサン酸誘導体 - Google Patents

中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての2-アミノ-5,5-ジメチルヘキサン酸誘導体 Download PDF

Info

Publication number
JP2024537619A
JP2024537619A JP2024514096A JP2024514096A JP2024537619A JP 2024537619 A JP2024537619 A JP 2024537619A JP 2024514096 A JP2024514096 A JP 2024514096A JP 2024514096 A JP2024514096 A JP 2024514096A JP 2024537619 A JP2024537619 A JP 2024537619A
Authority
JP
Japan
Prior art keywords
amino
methyl
acid
dimethyl
dimethylhexanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537619A5 (cg-RX-API-DMAC7.html
Inventor
ブライアン リトル,ポウル
ハビエル カセス-トーマス,マヌエル
フールサング キョルビー,マス
ニュケーア,アナス
Original Assignee
ベスパー バイオ アーペーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベスパー バイオ アーペーエス filed Critical ベスパー バイオ アーペーエス
Publication of JP2024537619A publication Critical patent/JP2024537619A/ja
Publication of JP2024537619A5 publication Critical patent/JP2024537619A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024514096A 2021-09-03 2022-09-02 中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての2-アミノ-5,5-ジメチルヘキサン酸誘導体 Pending JP2024537619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21194937.5 2021-09-03
EP21194937.5A EP4144352A1 (en) 2021-09-03 2021-09-03 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system
PCT/EP2022/074536 WO2023031440A1 (en) 2021-09-03 2022-09-02 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system

Publications (2)

Publication Number Publication Date
JP2024537619A true JP2024537619A (ja) 2024-10-16
JP2024537619A5 JP2024537619A5 (cg-RX-API-DMAC7.html) 2025-09-09

Family

ID=77640524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514096A Pending JP2024537619A (ja) 2021-09-03 2022-09-02 中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての2-アミノ-5,5-ジメチルヘキサン酸誘導体

Country Status (10)

Country Link
US (1) US20250268854A1 (cg-RX-API-DMAC7.html)
EP (2) EP4144352A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024537619A (cg-RX-API-DMAC7.html)
KR (1) KR20240056551A (cg-RX-API-DMAC7.html)
CN (1) CN118019533A (cg-RX-API-DMAC7.html)
AU (1) AU2022339056A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229686A1 (cg-RX-API-DMAC7.html)
IL (1) IL311208A (cg-RX-API-DMAC7.html)
MX (1) MX2024002696A (cg-RX-API-DMAC7.html)
WO (1) WO2023031440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
EP4342530A1 (en) * 2022-09-02 2024-03-27 Insusense ApS Sortilin modulators
EP4428122A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Sortiline modulators
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
TW202600557A (zh) * 2024-02-20 2026-01-01 日商大塚製藥股份有限公司 作為sort1抑制劑之哌啶-及嗎啉-羧酸鹽化合物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3230214A (en) * 1962-11-27 1966-01-18 Beecham Group Ltd Preparation of 6-aminoacylpenicillanic acids
JP2001163842A (ja) * 1999-12-06 2001-06-19 Tokuyama Corp アミノ酸エステル塩酸塩の製造方法
JP2005526753A (ja) * 2002-03-05 2005-09-08 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害剤
WO2008054475A2 (en) * 2006-03-13 2008-05-08 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
JP2011521893A (ja) * 2008-04-01 2011-07-28 ビロベイ,インコーポレイティド システインプロテアーゼ阻害剤としてのジフルオロ含有化合物
JP2016505063A (ja) * 2013-01-28 2016-02-18 ハー・ルンドベック・アクチエゼルスカベット ソルチリン阻害剤としてのn置換された5置換フタルアミド酸
JP2018538248A (ja) * 2015-10-23 2018-12-27 ナビター ファーマシューティカルズ, インコーポレイテッド セストリン−gator2相互作用のモジュレーターおよびその使用
JP2020517707A (ja) * 2017-04-26 2020-06-18 ナビター ファーマシューティカルズ, インコーポレイテッド Sestrin−GATOR2相互座用のモジュレーターおよびその使用
JP2023546366A (ja) * 2020-10-07 2023-11-02 インスセンセ アーペーエス 難聴の予防または処置における使用のためのソルチリンアンタゴニスト

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
EP4073116A1 (en) 2019-12-10 2022-10-19 Aarhus Universitet Compounds for treatment of eye diseases

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3230214A (en) * 1962-11-27 1966-01-18 Beecham Group Ltd Preparation of 6-aminoacylpenicillanic acids
JP2001163842A (ja) * 1999-12-06 2001-06-19 Tokuyama Corp アミノ酸エステル塩酸塩の製造方法
JP2005526753A (ja) * 2002-03-05 2005-09-08 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害剤
WO2008054475A2 (en) * 2006-03-13 2008-05-08 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
JP2011521893A (ja) * 2008-04-01 2011-07-28 ビロベイ,インコーポレイティド システインプロテアーゼ阻害剤としてのジフルオロ含有化合物
JP2016505063A (ja) * 2013-01-28 2016-02-18 ハー・ルンドベック・アクチエゼルスカベット ソルチリン阻害剤としてのn置換された5置換フタルアミド酸
JP2018538248A (ja) * 2015-10-23 2018-12-27 ナビター ファーマシューティカルズ, インコーポレイテッド セストリン−gator2相互作用のモジュレーターおよびその使用
JP2020517707A (ja) * 2017-04-26 2020-06-18 ナビター ファーマシューティカルズ, インコーポレイテッド Sestrin−GATOR2相互座用のモジュレーターおよびその使用
JP2023546366A (ja) * 2020-10-07 2023-11-02 インスセンセ アーペーエス 難聴の予防または処置における使用のためのソルチリンアンタゴニスト

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"CAS登録番号 2197322-13-5, 2197266-17-2, 2197232-76-9, 1262965-10-5, 1262965-07-0", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7026003258, 23 March 2018 (2018-03-23), ISSN: 0005913123 *
HARRIS, STANTON A.; FISHER, LINDA V. AND FOLKERS, KARL: "The synthesis of tenuazonic and congeneric tetramic acids", JOURNAL OF MEDICINAL CHEMISTRY, vol. 8(4), JPN6026030287, 1 July 1965 (1965-07-01), US, pages 478 - 482, ISSN: 0005913120 *
JACOB LAUWRING ANDERSEN, TENNA JUUL SCHRODER, SOREN CHRISTENSEN, DORTHE STRANDBYGARD, LONE TJENER PA: "Identification of the first small-molecule ligand of the neuronal receptor sortilin and structure de", ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY, vol. D70(2), JPN6026030294, 29 January 2014 (2014-01-29), pages 451 - 460, ISSN: 0005913125 *
MALLIGA R. IYER AND GEORGE KUNOS: "Therapeutic approaches targeting the neurotensin receptors", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 31(5), JPN6026030295, 8 January 2021 (2021-01-08), UK, pages 361 - 386, ISSN: 0005913126 *
MUKERJI, D. D. AND NAUTIYAL, S. R.: "Synthesis of some newer 3-substituted-4(3H)-quinazolinones. Part I", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 56(12), JPN6026030289, December 1979 (1979-12-01), IN, pages 1226 - 1229, ISSN: 0005913122 *
SHAWN J. STACHEL, ANTHONY T. GINNETTI, SCOTT A. JOHNSON, PAIGE CRAMER, YI WANG, MARINA BUKHTIYAROVA,: "Identification of potent inhibitors of the sortilin-progranulin interaction", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 30(17), JPN6026030293, 15 July 2020 (2020-07-15), US, pages 127403, ISSN: 0005913124 *
TENNA JUUL SCHRODER, SOREN CHRISTENSEN, SAMSA LINDBERG, MORTEN LANGGARD, LAURENT DAVID, PHILIP J. MA: "The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting recepto", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24(1), JPN6026030296, 27 November 2013 (2013-11-27), US, pages 177 - 180, ISSN: 0005913127 *
TOPUZYAN, V. O.; KARAPETYAN, I. R. AND ALEBYAN, G. P.: "Synthesis and anticholinesterase properties of choline esters of α-amino acids", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 48(3), JPN6026030288, 17 July 2014 (2014-07-17), US, pages 163 - 165, ISSN: 0005913121 *

Also Published As

Publication number Publication date
IL311208A (en) 2024-05-01
MX2024002696A (es) 2024-05-14
KR20240056551A (ko) 2024-04-30
EP4144352A1 (en) 2023-03-08
AU2022339056A1 (en) 2024-03-21
CA3229686A1 (en) 2023-03-09
EP4395776A1 (en) 2024-07-10
CN118019533A (zh) 2024-05-10
US20250268854A1 (en) 2025-08-28
WO2023031440A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
AU2022339056A1 (en) 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system
JP2020503300A (ja) 二環式oga阻害剤化合物
KR20240007137A (ko) 소르틸린 활성 조절제
JP2024517678A (ja) ソルチリン活性の修飾物質
TWI644916B (zh) 哌喃并二吡啶化合物
US20250161321A1 (en) Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases
TW202423910A (zh) 化合物
EP4032891A1 (en) Pyridine derivatives as modulators of sortilin activity
EP4428121A1 (en) Modulators of sortilin activity
EP4428124A1 (en) Modulators of sortilin activity
EP4676915A1 (en) Sortiline modulators
EP4428122A1 (en) Sortiline modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721